Allergy Concepts Inc.

Research from Medical University of Vienna, Department of Pathophysiology in immunotherapy provides new insights.
Vaccine Weekly; 11/18/2009; 1008 words; ...introduce different concepts of allergen modification...Clinical & Experimental Allergy (Genetic allergen modification...Clinical & Experimental Allergy, 2009;39(11...Clinical & Experimental Allergy is: Blackwell Publishing Inc., 350 Main St...Vienna, Allergen, Allergies, ...

Researchers from University of Colorado, Department of Medicine publish findings in inflammation.
Biotech Week; 11/18/2009; 1111 words; ...study highlights a novel concept on how different bacterial...Clinical & Experimental Allergy (A low dose of Mycoplasma...Clinical & Experimental Allergy, 2009;39(11...Clinical & Experimental Allergy is: Blackwell Publishing Inc., 350 Main St...Denver, Allergen, Allergies, ...

Ardea Biosciences Announces Additional Positive Results from a Phase 2a Study of RDEA594 at the 2009 ACR/ARHP Annual Scientific Meeting.
Chemicals & Chemistry Business; 11/6/2009; 1377 words; Ardea Biosciences, Inc. (Nasdaq: RDEA) announced...Phase 2a, proof-of-concept study of RDEA594, its...Head of the Section of Allergy and Clinical Immunology...Division of Pulmonary, Allergy and Critical Care Medicine...Chemistry, Ardea Biosciences Inc. This article was prepared...

Pharmacopeia Rises On Deal With Cephalon: $15M Up Front.
BIOWORLD Today; 11/3/2009; 1002 words; ...Pharmacopeia Drug Discovery Inc. jumped 26.3 percent...discovery deal with Cephalon Inc. that includes a $15...molecules to proof of concept, with Cephalon responsible...molecule for asthma and allergy partnered with Osaka...molecules to proof of concept in a range of therapeutic...

Clinic Roundup.
BIOWORLD Today; 11/3/2009; 932 words; ...fourth quarter. o VaxGen Inc., of Brisbane, Calif...National Institute of Allergy and Infectious Diseases. o Viral Genetics Inc., of Azusa, Calif...Toronto. o ViroPharma Inc., of Exton, Pa...achieved a proof-of-concept milestone, although analysis...